Literature DB >> 16465446

The urokinase receptor: a ligand or a receptor? Story of a sociable molecule.

P Ragno1.   

Abstract

In this last decade, the structure and functions of the receptor for the urokinase-type plasminogen activator have been extensively studied and characterized. This interesting receptor plays a key role in cell adhesion, migration and proliferation. It was identified 20 years ago as the specific cell-surface molecule that could bind and concentrate urokinase on the cell membrane, thus initiating the proteolytic cascade promoted by the activation of plasminogen. The identification of new extracellular ligands, such as vitronectin, and of cell-surface interactors, such as integrins and fMet-Leu-Phe receptors, shed new light on its possible roles, totally independent of the enzymatic properties of its ligand. uPAR ligands and interactors and the functional consequences of the multiple binding capability of this intriguing receptor are reviewed here.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465446     DOI: 10.1007/s00018-005-5428-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  43 in total

1.  Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Dzung H Dinh; Jeffrey D Klopfenstein; Jasti S Rao
Journal:  Cancer Lett       Date:  2011-09-06       Impact factor: 8.679

2.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

Review 3.  GPI-AP release in cellular, developmental, and reproductive biology.

Authors:  Yoshitaka Fujihara; Masahito Ikawa
Journal:  J Lipid Res       Date:  2015-11-22       Impact factor: 5.922

4.  The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.

Authors:  Nunzia Montuori; Katia Bifulco; Maria Vincenza Carriero; Claudio La Penna; Valeria Visconte; Daniela Alfano; Ada Pesapane; Francesca Wanda Rossi; Salvatore Salzano; Guido Rossi; Pia Ragno
Journal:  Cell Mol Life Sci       Date:  2010-10-24       Impact factor: 9.261

5.  Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.

Authors:  Audrey M Bernstein; Sally S Twining; Debra J Warejcka; Edward Tall; Sandra K Masur
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

6.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

7.  A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.

Authors:  Elizabeth Monaghan-Benson; Cynthia Corley Mastick; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

8.  Participation of the urokinase receptor in neutrophil efferocytosis.

Authors:  Young-Jun Park; Gang Liu; Yuko Tsuruta; Emmanuel Lorne; Edward Abraham
Journal:  Blood       Date:  2009-04-27       Impact factor: 22.113

9.  Olfactory imprinting of amino acids in lacustrine sockeye salmon.

Authors:  Yuzo Yamamoto; Hiroshi Hino; Hiroshi Ueda
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

10.  Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.

Authors:  H Taubert; P Würl; T Greither; M Kappler; M Bache; C Lautenschläger; S Füssel; A Meye; A W Eckert; H-J Holzhausen; V Magdolen; M Kotzsch
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.